Increases in resting heart rate are a recognised class effect of incretin-based therapies and have been reported with GLP-1 receptor agonists more broadly, as reflected in the Summary of Product Characteristics (SmPC) for licensed agents such as semaglutide (Wegovy) and liraglutide (Saxenda)
Wegovy commonly causes gastrointestinal side effects including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation
Typically, the positive effects last from about a week up to a month, though this can vary based on how your body absorbs and utilizes the vitamin, as well as your overall health
Milder or dietary deficiency: Sometimes a less intensive approach (e.g
While compounded Tirzepatide and Semaglutide were vital during the shortage, now that supply chains are stabilizing, the FDA is tightening its grip
Molecular weight confirmation through mass spectrometry verifies you received the correct peptide rather than a cheaper substitute
